Pharsight

Spiriva generic

Spiriva is approved for treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD). It is owned by Boehringer Ingelheim. It contains the active ingredient Tiotropium Bromide. It was first authorized for medical use in 2004. The global pulmonary/respiratory market size was estimated at US$ 53 billion in 2021 and it is projected to surpass around US$ 87 billion by 2029. There were 12 drug patents protecting Spiriva in United States, but as of now 7 of those patents have expired.

When will Spiriva generic be available?

Spiriva (Tiotropium Bromide) currently has patent protection until April 19, 2030. This means Spiriva generic become available in the market after April 19, 2030 , unless a Paragraph IV certification was filed challenging the patents before expiration.

Spiriva uses

Spiriva is an inhaled medication approved for long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is also approved for treating asthma in patients aged 6 years and older. The active ingredient in Spiriva is Tiotropium Bromide, an anticholinergic agent which works by relaxing muscles in the airways to open up the airways and make breathing easier.

Spiriva patent expiration

Spiriva currently holds 12 patents covering various aspects, including the active ingredient and formulation. With patents lasting over 7 more years, patent expiration will prevent Spiriva generic until 19 April, 2030. Below is a list of the recent Spiriva patent expirations -

EPO Oppostions filed on Spiriva

Spiriva dosage

Want to ask something?